Serious infection from Staphylococcus aureus in 2 HIV-infected patients receiving fusion inhibitor therapy.
Fusion inhibitors are novel antiretroviral agents, administered as subcutaneous injections, approved for use in treatment-experienced HIV-infected patients. HIV-infected patients are at increased risk for Staphylococcus aureus colonization, specifically with methicillin-resistant S aureus (MRSA), and subsequent systemic infection. We present the cases of 2 patients without a history of MRSA infection in whom a series of severe S aureus infections developed after fusion inhibitor therapy.
Gaughan
Elizabeth M
EM
Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Ritter
Michelle L
ML
Kumar
Princy N
PN
Timpone
Joseph G
JG
D016470:Bacteremia / Q000382:microbiology; D000077560:Enfuvirtide; D017809:Fatal Outcome; D015700:HIV Envelope Protein gp41 / Q000008:administration & dosage / Q000009:adverse effects*; D023581:HIV Fusion Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D016106:Methicillin Resistance / Q000187:drug effects*; D008875:Middle Aged; D010446:Peptide Fragments / Q000008:administration & dosage / Q000009:adverse effects*; D012307:Risk Factors; D013203:Staphylococcal Infections / Q000209:etiology* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects*
D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide